Acer Therapeutics Inc. (NASDAQ:ACER) shares traded -10.36% lower at $3.72 on Wall Street last session.
In accordance with the data, 3 analysts cover Acer Therapeutics Inc. (NASDAQ:ACER). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $12.00 and a low of $7.00, we find $10.00. Given the previous closing price of $4.15, this indicates a potential upside of 140.96 percent. ACER stock price is now 122.95% away from the 50-day moving average and 106.56% away from the 200-day moving average. The market capitalization of the company currently stands at $68.00M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
It has been rated a hold by 0 analysts and a buy by 3. Brokers who have rated the stock have averaged $9.67 as their price target over the next twelve months.
With the price target reduced from $55 to $10, H.C. Wainwright maintained Buy rating for Acer Therapeutics Inc. (NASDAQ: ACER)., while ‘Raymond James’ rates the stock as ‘Mkt Perform’.
In other news, ASELAGE STEVE, Director bought 409,836 shares of the company’s stock on Nov 29. The stock was bought for $500,000 at an average price of $1.22. Upon completion of the transaction, the Director now directly owns 483,741 shares in the company, valued at $1.8 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 29, President & CEO Schelling Chris bought 819,672 shares of the business’s stock. A total of $1,000,000 was incurred on buying the stock at an average price of $1.22. This leaves the insider owning 2,712,529 shares of the company worth $10.09 million. A total of 19.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ACER stock. A new stake in Acer Therapeutics Inc. shares was purchased by SUSQUEHANNA INTERNATIONAL GROUP, LLP during the first quarter worth $60,000. In total, there are 33 active investors with 26.10% ownership of the company’s stock.
Acer Therapeutics Inc. (NASDAQ: ACER) opened at $4.1800 on Friday. During the past 12 months, Acer Therapeutics Inc. has had a low of $1.11 and a high of $4.24. The fifty day moving average price for ACER is $1.7180 and a two-hundred day moving average price translates $1.8071 for the stock.
The latest earnings results from Acer Therapeutics Inc. (NASDAQ: ACER) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.17, beating analysts’ expectations of -$0.57 by 0.4. This compares to -$0.23 EPS in the same period last year.
Acer Therapeutics Inc.(ACER) Company Profile
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
